Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Targeted Therapy
  •  Radiation Oncology
  •  Pancreatic Cancer
  •  Chemotherapy and Radiotherapy
  •  Ovarian Cancer
  •  Blood Cancer
  •  Endoscopy Methods
  •  Cervical Cancer

Abstract

Citation: Clin Oncol. 2021;6(1):1833.DOI: 10.25107/2474-1663.1833

The Expression Profile of Bcl-2 Protein in Prostate Cancer Patients

Eman Alshahmi, Esra Obida, Fatma Emaetig, Fauzia Elgaraboli and Omar Alqawi

Department of Zoology, Misurata University, Libya
Department of Histopathology, National Cancer Institute, Libya
Department of Genetics, Misurata University, Libya
Biotechnology Research Centre-Misurata, National Cancer Institute, Libya

*Correspondance to: Omar Alqawi 

 PDF  Full Text Research Article | Open Access

Abstract:

Background: The Bcl-2 oncoprotein inhibits programmed cell death or apoptosis. Over production of Bcl-2 protein occurs in a wide variety of human cancers including prostate cancer and presumably contributes to tumor expansion by prolonging cell survival through inhibition of apoptosis.
Objectives: This study aims to evaluate the Bcl-2 expression in benign prostatic hyperplasia and prostate cancer tissues. In addition, it focuses on finding the association of Bcl-2 protein expression in prostate malignant tissues with the clinical data of the patients such as age and tumor stage.
Materials and Methods: Tissue samples from 49 patients with prostate diseases included 40 adenocarcinoma and 9 benign prostate hyperplasia cases. The patients underwent curative surgical prostatectomy or prostate true cut biopsy at National Cancer Institute (NCI)-Misurata at the period from 2016 to 2018. Immunoreactivity for Bcl-2 expression was examined by immunohistochemistry method. The clinical and histopathological information included age and Gleason score was collected from the patients' files.
Results: Among the studied 40 cases of adenocarcinoma 22/40 (55%) showed positive immunostaining of Bcl-2 protein. The statistical analysis of the results revealed that there was no significant correlation between Bcl-2 expression level in benign and in cancer prostate tissues (p-value =0.485). In addition, no significant association between Bcl-2 expression and the age or the
tumor stage of patients.
Conclusion: Our data revealed that the predictive and prognostic role of Bcl-2 protein in prostate cancer was not noticed in this study.

Keywords:

Prostate cancer; Bcl-2 protein; Apoptosis; Immunohistochemistry

Cite the Article:

Alshahmi E, Obida E, Emaetig F, Elgaraboli F, Alqawi O. The Expression Profile of Bcl-2 Protein in Prostate Cancer Patients. Clin Oncol. 2021;6:1833..

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

First Successful Experience of Organ-Preserving Endoscopic Surgical Treatment for Upper Urinary Tract Urothelial Carcinoma
 Abstract  PDF  Full Text
High CDX2 Expression Predicts a Favorable Prognosis in Patients with Early-Stage Gastric Adenocarcinoma
 Abstract  PDF  Full Text
View More...